Wave Life Sciences Achieves First-Ever Therapeutic RNA Editing In Humans With Results From RestorAATion-2 Trial Of WVE-006 For Alpha-1 Antitrypsin Deficiency

Benzinga · 10/16 12:37

Single Dose Raises Wild-Type M-AAT Levels To 60% Of Total AAT, With Durable Effects Observed Through 57 Days; Multidose Data Expected In 2025